SYNGAP1 and autism spectrum disorder: Deleterious variants in SYNGAP1 have been identified in a variety of phenotypically defined cohorts including syndromic/non-syndromic intellectual disability, autism spectrum disorder, and epileptic encephalopathy [4, 6, 13, 15, 16].